TREATMENT CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS, TEMOZOLOMIDE AND/OR RADIATION THERAPY

Title:

TREATMENT CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS, TEMOZOLOMIDE AND/OR RADIATION THERAPY

Document Type and Number:

WIPO Patent Application WO/2019/015561

Kind Code:

A1

Abstract:

Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and/or radiation therapy. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and the use thereof.

Inventors:

WANG LAI (CN)
TANG ZHIYU (CN)
LUO LUSONG (CN)
WEI MIN (CN)
PETERSON AMY (CN)
WANG HEXIANG (CN)
REN BO (CN)
ZHOU CHANGYOU (US)

Application Number:

PCT/CN2018/095911

Publication Date:

January 24, 2019

Filing Date:

July 17, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

BEIGENE LTD (KY)
WANG LAI (CN)

International Classes:

A61K31/4188; A61K31/551; A61N5/10; A61P35/00; C07D487/06; C07D487/22

Domestic Patent References:

WO2013097225A1	2013-07-04
WO2017032289A1	2017-03-02

Other References: